Important information
Due to legal restrictions, this part of Phase Holographic Imaging PHI AB’s (“PHI”) website is not accessible to certain persons. We therefore ask you to read the following information and provide the following acknowledgement each time you wish to access these web pages. Please note that the terms and conditions below may be changed or updated, and it is therefore important that you read them each time you visit this page.
The information on this part of PHI’s website is not intended for, and may not, directly or indirectly, in whole or in part, be accessed by, distributed or disseminated to persons residing or located in the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where/if such distribution requires additional prospectuses, registration or other measures than those required by Swedish law or otherwise contravenes the rules of such jurisdiction or cannot be done without the application of an exemption from such measure. The information on the websites does not constitute an offer of shares, subscription rights, paid subscribed shares or other securities issued by PHI (‘Securities’) to any person in such jurisdictions. The information on the web pages may not be forwarded or reproduced in a manner that is in conflict with such restrictions or would involve such requirements. No Securities have been or will be registered under the United States Securities Act of 1933, as amended (the ‘Securities Act’), or under any corresponding law of any state or other jurisdiction of the United States and may not be offered, subscribed for, exercised, pledged, sold, resold, delivered or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and the assigned, delivered or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction of the United States.
Within the European Economic Area (‘EEA’), no offer of Securities is being made to the public in any country other than Sweden. In other member states of the European Union (‘EU’), such an offer may only be made in accordance with exemptions in the Prospectus Regulation (EU) 2017/1129 (the ‘Prospectus Regulation’). In other countries in the EEA that have implemented the Prospectus Regulation in national legislation, such an offer may only be made in accordance with exemptions in the Prospectus Regulation and in accordance with any relevant implementing measure. In other countries in the EEA that have not implemented the Prospectus Regulation in national legislation, such an offer may only be made in accordance with the applicable exemption in the national legislation. In order to be entitled to access the information on the following website, if you access the following website, you shall be deemed to have confirmed and represented that (i) you have read and accept the terms and restrictions set out above, and (ii) you are not located in the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction where the release, distribution or publication would be unlawful under applicable law or regulation.
Rights Issue 2024
Summary
- The rights issue amounts to approximately SEK 64.3 million before deduction of issue related costs. The capitalization is intended to fund the company’s operations until at least Q1 2026 as well as strengthen the company’s capital structure by repayment/off-setting of outstanding loans leading to PHI being debt free of interest-bearing liabilities post-transaction.
- The rights issue is secured in writing to 100 percent through pre-subscription- and underwriting commitments, as set out below:
- Altium has provided a pre-subscription commitment of approximately SEK 15.2 million, corresponding to approximately 23.6 percent of the rights issue, which is equal to Altium’s pro-rata holdings in PHI.
- Altium has, in addition to the pre-subscription commitment, provided a top-down underwriting (from 100 percent down) commitment of approximately SEK 20.5 million, corresponding to approximately 31.8 percent of the rights issue, which is equal to the outstanding convertible loan amount (and its accumulated interest) held by Altium.
- A consortium of external qualified underwriters has provided bottom underwriting commitments totalling approximately SEK 28.7 million, corresponding to approximately 44.6 percent of the rights issue and stems from the pre-subscribed level of 23.6 percent, up to the top-down underwriting commitment.
- The subscription price in the rights issue is set to SEK 1.80 per share.
- The subscription period in the rights issue runs from 6-20 December 2024.